UBS analyst Dan Leonard downgraded Thermo Fisher (TMO) to Neutral from Buy with a price target of $460, down from $500, citing the view that “a confluence of headwinds” could pressure life sciences R&D longer than many expect. The firm, which notes that this end market comprises about 50% of Thermo’s sales, notes that its 2026 organic sales growth forecast of 4% is 200 basis points below the Street view and it lowered forecasts for the outer years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher announces FDA approved Oncomine Dx Express Test
- Thermo Fisher’s Strategic Acquisition Adjustment Enhances Financial Prospects and Justifies Buy Rating
- NIH directs staff not to end any extra research projects for now, NY Times says
- Adial Pharmaceuticals secures U.S.-based manufacturing through agreements
- Thermo Fisher price target lowered to $450 from $475 at Barclays